Syneos Health (NASDAQ:SYNH) issued an update on its FY 2019 earnings guidance on Monday morning. The company provided earnings per share guidance of $3.03-3.23 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.07. The company issued revenue guidance of $4.62-4.73 billion, compared to the consensus revenue estimate of $4.68 billion.
Shares of NASDAQ:SYNH traded up $0.50 on Monday, hitting $47.42. The company had a trading volume of 884,527 shares, compared to its average volume of 781,267. The company has a quick ratio of 0.97, a current ratio of 0.97 and a debt-to-equity ratio of 0.99. Syneos Health has a 52-week low of $34.40 and a 52-week high of $56.34. The company has a market capitalization of $4.29 billion, a P/E ratio of 24.44, a P/E/G ratio of 1.19 and a beta of 1.41.
Several analysts have recently issued reports on SYNH shares. SunTrust Banks reduced their price objective on Syneos Health to $55.00 and set a buy rating on the stock in a research report on Wednesday, December 19th. Zacks Investment Research lowered Syneos Health from a buy rating to a hold rating in a research note on Friday, November 30th. ValuEngine upgraded Syneos Health from a hold rating to a buy rating in a research note on Monday, February 4th. Barclays dropped their target price on Syneos Health from $51.00 to $45.00 and set an equal weight rating for the company in a research note on Thursday, January 3rd. Finally, Robert W. Baird set a $60.00 target price on Syneos Health and gave the company a buy rating in a research note on Tuesday, January 8th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Syneos Health currently has a consensus rating of Buy and an average price target of $53.44.
In related news, CEO Alistair Macdonald sold 6,697 shares of the company’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $53.04, for a total value of $355,208.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.57% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2019/03/18/syneos-health-synh-updates-fy-2019-earnings-guidance.html.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
See Also: Are all No-Load Funds Equal?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.